$19.52
7.94% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

IDEAYA Biosciences Inc Target price 2025 - Analyst rating & recommendation

IDEAYA Biosciences Inc Classifications & Recommendation:

Buy
92%
Hold
8%

IDEAYA Biosciences Inc Price Target

Target Price $51.42
Price $19.63
Potential
Number of Estimates 12
12 Analysts have issued a price target IDEAYA Biosciences Inc 2026 . The average IDEAYA Biosciences Inc target price is $51.42. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 12 Analysts recommend IDEAYA Biosciences Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the IDEAYA Biosciences Inc stock has an average upside potential 2026 of . Most analysts recommend the IDEAYA Biosciences Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 7.00 14.64
70.07% 109.17%
EBITDA Margin -4,637.00% -2,040.58%
721.97% 55.80%
Net Margin -4,203.36% -1,917.86%
472.82% 54.37%

12 Analysts have issued a sales forecast IDEAYA Biosciences Inc 2025 . The average IDEAYA Biosciences Inc sales estimate is

$14.6m
Unlock
. This is
109.17% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$34.2m 388.57%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $7.0m 70.07%
2025
$14.6m 109.17%
Unlock
2026
$56.3m 284.79%
Unlock
2027
$177m 213.96%
Unlock
2028
$337m 90.48%
Unlock
2029
$637m 89.10%
Unlock

3 Analysts have issued an IDEAYA Biosciences Inc EBITDA forecast 2025. The average IDEAYA Biosciences Inc EBITDA estimate is

$-299m
Unlock
. This is
16.18% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-282m 20.94%
Unlock
, the lowest is
$-325m 8.89%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-325m 145.99%
2025
$-299m 7.54%
Unlock
2026
$-288m 3.65%
Unlock
2027
$-106m 63.31%
Unlock

EBITDA Margin

2024 -4,637.00% 721.97%
2025
-2,040.58% 55.80%
Unlock
2026
-510.96% 74.96%
Unlock
2027
-59.71% 88.31%
Unlock

4 IDEAYA Biosciences Inc Analysts have issued a net profit forecast 2025. The average IDEAYA Biosciences Inc net profit estimate is

$-281m
Unlock
. This is
10.68% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-233m 25.91%
Unlock
, the lowest is
$-323m 2.78%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-294m 71.43%
2025
$-281m 4.56%
Unlock
2026
$-300m 6.93%
Unlock
2027
$-244m 18.82%
Unlock
2028
$-202m 17.02%
Unlock
2029
$46.4m 122.94%
Unlock

Net Margin

2024 -4,203.36% 472.82%
2025
-1,917.86% 54.37%
Unlock
2026
-532.95% 72.21%
Unlock
2027
-137.81% 74.14%
Unlock
2028
-60.04% 56.43%
Unlock
2029
7.28% 112.13%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.36 -3.21
71.43% 4.46%
P/E negative
EV/Sales 71.90

4 Analysts have issued a IDEAYA Biosciences Inc forecast for earnings per share. The average IDEAYA Biosciences Inc EPS is

$-3.21
Unlock
. This is
10.58% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.66 25.91%
Unlock
, the lowest is
$-3.69 2.79%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.36 71.43%
2025
$-3.21 4.46%
Unlock
2026
$-3.43 6.85%
Unlock
2027
$-2.78 18.95%
Unlock
2028
$-2.31 16.91%
Unlock
2029
$0.53 122.94%
Unlock

P/E ratio

Current -5.47 72.97%
2025
-6.12 11.88%
Unlock
2026
-5.72 6.54%
Unlock
2027
-7.05 23.25%
Unlock
2028
-8.50 20.57%
Unlock
2029
37.04 535.76%
Unlock

Based on analysts' sales estimates for 2025, the IDEAYA Biosciences Inc stock is valued at an EV/Sales of

71.90
Unlock
and an P/S ratio of
117.42
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 150.38 1.55%
2025
71.90 52.19%
Unlock
2026
18.68 74.01%
Unlock
2027
5.95 68.15%
Unlock
2028
3.12 47.50%
Unlock
2029
1.65 47.12%
Unlock

P/S ratio

Current 245.60 24.27%
2025
117.42 52.19%
Unlock
2026
30.52 74.01%
Unlock
2027
9.72 68.15%
Unlock
2028
5.10 47.50%
Unlock
2029
2.70 47.12%
Unlock

Current IDEAYA Biosciences Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Stephens & Co.
Locked
Locked
Locked Feb 14 2025
RBC Capital
Locked
Locked
Locked Jan 15 2025
Cantor Fitzgerald
Locked
Locked
Locked Jan 13 2025
Cantor Fitzgerald
Locked
Locked
Locked Dec 17 2024
Wedbush
Locked
Locked
Locked Dec 17 2024
Stephens & Co.
Locked
Locked
Locked Nov 18 2024
Leerink Partners
Locked
Locked
Locked Nov 05 2024
Analyst Rating Date
Locked
Stephens & Co.:
Locked
Locked
Feb 14 2025
Locked
RBC Capital:
Locked
Locked
Jan 15 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Jan 13 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Dec 17 2024
Locked
Wedbush:
Locked
Locked
Dec 17 2024
Locked
Stephens & Co.:
Locked
Locked
Nov 18 2024
Locked
Leerink Partners:
Locked
Locked
Nov 05 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today